论文部分内容阅读
目的探讨2型糖尿病患者血清α-L-岩藻糖苷酶与微血管病变的关系。方法将135例2型糖尿病患者分为A、B两组:A组为合并微血管病变者70例;B组为无微血管病变者65例;同时选取80例健康对照者,分别检测各组人群的α-L-岩藻糖苷酶,分析它们在正常人和糖尿病患者之间有何不同。结果糖尿病合并微血管病变组的α-L-岩藻糖苷酶明显高于无微血管病变组(P<0.05);无微血管病变组与健康对照组之间无统计学差异(P>0.05)。结论α-L-岩藻糖苷酶的检测对2型糖尿病患者合并微血管病变的诊疗具有一定价值,可作为2型糖尿病患者微循环障碍的临床观察指标。
Objective To investigate the relationship between serum α-L-fucosidase and microangiopathy in type 2 diabetic patients. Methods One hundred and thirty-five patients with type 2 diabetes were divided into two groups: A group with 70 cases with microvascular disease; B group with 65 cases without microvascular disease; 80 healthy controls were selected at the same time, α-L-fucosidase and analyze how they differ between normal and diabetic patients. Results The α-L-fucosidase in diabetic patients with microvascular disease was significantly higher than those without microvascular disease (P <0.05). There was no significant difference between the patients without microangiopathy and healthy controls (P> 0.05). Conclusion The detection of α-L-fucosidase has some value in the diagnosis and treatment of patients with type 2 diabetes mellitus with microvascular disease, and can be used as a clinical observation index for patients with type 2 diabetes mellitus.